Recent clinical trials exhibited similar effects on preventing tumour bone metastasis by treatment with the anti-RANKL agent denosumab, which disrupts the RANK-RANKL signalling involved in osteoclastogenesis [69–72]. Here, TNFSF11 is linked to neoplasm.